Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director
King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment bankin
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-31 10:15 AM EDT | Phio Pharmaceuticals Corp.
PharmaDrug Announces Debt Restructuring
Toronto, Ontario--(Newsfile Corp. - October 31, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has agreed to issue $445,686 principal amount of secured convertible debentures to two current holders of the Company's secured convertible debentures that were past their maturity date. Each Debe
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-10-31 8:58 AM EDT | PharmaDrug Inc.
Anne-Kathrin Stoller to Become New CEO at Bachem
Bubendorf, Switzerland--(Newsfile Corp. - October 31, 2025) - Ad hoc announcement pursuant to Art. 53 LR Anne-Kathrin Stoller to become new CEO at Bachem Bachem (SIX: BANB) announced today that its Board of Directors has appointed Anne-Kathrin Stoller, currently Head of Bachem Americas and previously the company's long-standing Chief Marketing Officer (CMO), as its new CEO, effective January 1, 2026. She succeeds Thomas Meier, wh
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-31 2:23 AM EDT | Bachem Holding AG
Hemostemix's Boots on the Ground in Florida October Update
Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, today announced major progress in Flori
Biotechnology, Pharmaceuticals, Health
2025-10-30 11:29 AM EDT | Hemostemix Inc.
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
Toronto, Ontario--(Newsfile Corp. - October 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is pleased to announce that it has executed a definitive securities exchange agreement (the "Definitive Agreement") with Canurta Limited Partnership ("Canurta") and each of the limited partners of Canurta, the parent en
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-10-30 9:00 AM EDT | PharmaDrug Inc.
BioHarvest Sciences Announces Strategic CDMO Partnership to Revolutionize Saffron Compound Production with Botanical Synthesis
British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pione
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:30 AM EDT | BioHarvest Sciences Inc.
PreveCeutical Closes Second Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases of August 5, 2025, September 5, 2025 and October 10, 2025 it has closed a second tranche (the "Second Tranche
Biotechnology, Pharmaceuticals, Health
2025-10-30 7:00 AM EDT | PreveCeutical Medical Inc.
Quantum BioPharma Ltd. Announces Corporate Updates
Toronto, Ontario--(Newsfile Corp. - October 29, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces, as approved by the shareh
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-29 9:00 PM EDT | Quantum BioPharma Ltd.
Microbiome Labs Expands Portfolio with Launch of Women's Health Line
Franklinton, North Carolina--(Newsfile Corp. - October 29, 2025) - Microbiome Labs, a leader in microbiome-based solutions, today announced the launch of its new Women's Health line. The collection debuts with two targeted formulations - Vaginal Balance and Pregnancy Support - designed to promote women's health through probiotic and nutrient blends with clinical evidence behind the ingredients. For decades, the gut has dominated the probiotic conversation. But another microbiome is crit
2025-10-29 11:40 AM EDT | Microbiome Labs
Envoy Medical Marks Three-Year Anniversary of First Patient Receiving Its Breakthrough Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - October 29, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the three-year anniversary of the first patient receiving its breakthrough first fully implanted cochlear implant. On October 24, 2022, Craig Eggert became the first patient in the world to be implanted with Envoy Medical's new investigational fully implanted cochlear impl
Biotechnology, Healthcare and Hospitals
2025-10-29 8:00 AM EDT | Envoy Medical, Inc.
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI
Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from pain related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce a one-hour educa
Biotechnology, Pharmaceuticals, Health
2025-10-28 3:44 PM EDT | Hemostemix Inc.
AquaBounty Technologies Announces Third Quarter 2025 Financial Results
Harvard, Massachusetts--(Newsfile Corp. - October 28, 2025) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the third quarter and nine months ended September 30, 2025. Third Quarter 2025 Highlights Net loss for the quarter ended September 30, 2025 was $1.4 mill
Agriculture, Biotechnology, Food / Beverages
2025-10-28 8:00 AM EDT | AquaBounty Technologies, Inc.
Izotropic Launches "Breast Imaging News" Page on BreastCT.com
Sacramento, California--(Newsfile Corp. - October 28, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce the launch of the "Breast Im
2025-10-28 8:00 AM EDT | Izotropic Corporation
IR-MED's Key Clinical and Media Milestones
Rosh Pina, Israel--(Newsfile Corp. - October 27, 2025) - IR-Med Inc. (OTCQB: IRME), (the "Company" or "IR-Med"), a medical technology company developing a non-invasive, AI-powered infrared spectroscopy platform for the assessment of pressure injuries and diabetic ulcers, today announced a series of recent milestones that highlight the Company's expanding visibility within the healthcare, investment, and media communities. Podium Presentation at Magnet & Pathway 2025 Confer
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-10-27 4:05 PM EDT | IR-MED, Inc.
Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain(TM) Manufacturer-to-Patient Blockchain-Enabled Tracking & Dispensing Platform for Prescription Drug Market
Florida and Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced that it has entered into a software as a service (SAAS) agreement with DataVault AI, Inc. (NASDAQ: DVLT) ("DataVault"), a pioneering technology company leading the way in AI data experie
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Blockchain
2025-10-27 9:42 AM EDT | Wellgistics Health
Zenith Epigenetics' ZEN-3694 Receives Orphan Drug Designation from FDA
Alberta and Amsterdam, Netherlands--(Newsfile Corp. - October 27, 2025) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug designation to ZEN-3694 for treatment of NUT carcinoma. NUT carcinoma is a rare, aggressive form of cancer with no currently approved treatments and significant unmet medical need. The Company recently announced
2025-10-27 8:30 AM EDT | Zenith Capital Corp.
Envoy Medical Receives Positive Listing Determination from NASDAQ
White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the Nasdaq Hearings Panel (the "Panel) has granted the Company's request for continued listing on the Nasdaq Stock Market. In granting the extension, the Panel considered several key developments, including Envoy Medical's recent equity capital raises and debt e
Biotechnology, Healthcare and Hospitals
2025-10-27 8:00 AM EDT | Envoy Medical, Inc.
TempraMed to Support Beyond Type 1's Beyond Type Run Team at the 2025 TCS New York City Marathon
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") the innovator behind the VIVI product line of temperature-protective solutions for injectable medications, is proud to announce its in-kind partnership of Beyond Type 1's 2025 TCS New York City Marathon initiative, Beyond Type Run. Through this partnership, TempraMed joins Beyond Type 1 in empowering 55 inspiring
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-27 7:00 AM EDT | TempraMed Technologies Ltd
Izotropic CEO Interview: IzoView Differentiators, Regulatory Plans, and Outlook
Sacramento, California--(Newsfile Corp. - October 23, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the release of a new video interview
2025-10-23 8:00 AM EDT | Izotropic Corporation
Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025
Montreal, Quebec--(Newsfile Corp. - October 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the performance of its Accum® technology in enhancing the efficacy of antibody-drug conjugates (ADCs) at the 16th World ADC Conference in San Diego, CA, USA
Biotechnology, Pharmaceuticals, Health
2025-10-23 3:15 AM EDT | Defence Therapeutics Inc.